← Back to Search

Monoclonal Antibodies

Alemtuzumab for Sickle Cell Disease

Phase < 1
Waitlist Available
Led By Kathleen Dorritie, MD
Research Sponsored by Kathleen Dorritie
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 100 days after hsct
Awards & highlights

Study Summary

This trial is testing a new stem cell transplant treatment for sickle cell disease using a matched donor.

Eligible Conditions
  • Sickle Cell Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 100 days after hsct
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 100 days after hsct for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Treatment Success
Secondary outcome measures
Changes in monthly transfusions after HSCT
Changes in the annual frequency of SCD-related hospitalization after
Therapeutic immunosuppression
+10 more

Side effects data

From 2017 Phase 4 trial • 8 Patients • NCT01395316
13%
Hypothyroidism
100%
80%
60%
40%
20%
0%
Study treatment Arm
Alemtuzumab

Trial Design

1Treatment groups
Experimental Treatment
Group I: Non Myeloablative regimen (Alemtuzumab)Experimental Treatment3 Interventions
Sickle cell patient receives sibling donor peripheral blood stem cell transplant with non-myeloablative pre-transplant conditioning.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Alemtuzumab
2004
Completed Phase 4
~1890
Total Body Irradiation
2006
Completed Phase 3
~820
Sirolimus
2013
Completed Phase 4
~2750

Find a Location

Who is running the clinical trial?

Kathleen DorritieLead Sponsor
1 Previous Clinical Trials
34 Total Patients Enrolled
Kathleen Dorritie, MDPrincipal Investigator - UPMC Hillman Cancer Center
University of Pittsburgh

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Stem Cell Transplant in Patients With Severe Sickle Cell Disease
Kathleen Dorritie 2018. "Stem Cell Transplant in Patients With Severe Sickle Cell Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03421756.
~0 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top